| CAS: | 138982-67-9 | |
| 分子式: | C21H21ClN4OS·HCl·H2O | |
| 分子量: | 449.39(as Anhydrous) | |
| 中文名称: |
| |
| 英文名称: |
| |
| 用途: | 用于医药,主治糖尿病。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Z858470 | MACKLIN | 齐拉西酮盐酸盐 一水合物 | 98%(HPLC) | 199元/250mg; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||
储存:室温,干燥 状态:白色到粉色粉末,晶体和/或块状 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z0032 | TCI | Ziprasidone Hydrochloride Monohydrate | >98.0%(HPLC) | 160元/50MG; 505元/250MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
技术规格
相关法规
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 186095 | J&K | Ziprasidone Hydrochloride Monohydrate | 99%, 一种有效的dopamine 和 serotonin (5-HT) receptor的拮抗剂 | 298元/250mg; 983元/1G; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||
基本信息
产品描述 Ziprasidone hydrochloride monohydrate (CP 88059 hydrochloride monohydrate) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity. Target: 5-HT receptor; Dopamine receptor Ziprasidone hydrochloride monohydrate is the salt form of ziprasidone, which possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, Ziprasidone hydrochloride monohydrate antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone hydrochloride monohydrate also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone hydrochloride monohydrate sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to Ziprasidone hydrochloride monohydrate, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone hydrochloride monohydrate was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3]. Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; Schizophrenia FDA Approved Date: February 2001 靶点(IC50 & Targe) 5-HT transporter,53nM(Ki) 5-HT1A,12Nm(Ki) 5-HT1B,4.0nM(Ki) 5-HT1D,2.3nM(Ki) 5-HT2A,0.6nM(Ki) 5-HT2C,13nM(Ki) 5-HT6,61nM(Ki) 5-HT7,6nM(Ki) D1,30nM(Ki) D2,6.8nM(Ki) D3,7.2nM(Ki) H1 receptor,63nM(Ki) norepinephrine transporter (NET),48nM(Ki) α1A-adrenergic receptor,18nM(Ki) α2A-adrenergic receptor,160nM(Ki) 参考文献 [1]. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. The Journal of Clinical Psychiatry. 2004, 65(2):217-221. [2]. Paul E. Keck, Marcio Versiani, Steven Potkin, et al. Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial. Am J Psychiatry 2003;160:741-748. [3]. Glen L. Stimmel, Mary A. Gutierrez, Vivian Lee. Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics, 2002, 24(1):21-37. [4]. Anne W Schmidt, Lorraine A Lebel, Harry R Howard Jr. et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. European Journal of Pharmacology. 2001,425(3):197-201. [5]. Ziprasidone 安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| C46243 | Alfa Aesar | Ziprasidone Hydrochloride Monohydrate | 1720元/250mg; 5753元/1g; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
基本信息 Ref# 分子式 分子量 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0001241 | Ziprasidone for system suitability 2 | European Pharmacopoeia (EP) Reference Standard | 1861.35元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 Ziprasidone is an atypical antipsychotic; FDA approved for the treatment of schizophrenia. 包装 Unit quantity: 0.465 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0001286 | Ziprasidone Hydrochloride Monohydrate | European Pharmacopoeia (EP) Reference Standard | 1277.32元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 Ziprasidone is an atypical antipsychotic; FDA approved for the treatment of schizophrenia. 包装 Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Y0001272 | Ziprasidone for system suitability 1 | European Pharmacopoeia (EP) Reference Standard | 2294.95元/ ; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 生化/生理作用 Ziprasidone is an atypical antipsychotic; FDA approved for the treatment of schizophrenia. 包装 Unit quantity: 10 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 注意 Please find SDS provided by EDQM here.. 其他说明 Sales restrictions may apply. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1724408 | USP | Ziprasidone hydrochloride | United States Pharmacopeia (USP) Reference Standard | 3231.47元/200 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生理作用 Ziprasidone is an atypical antipsychotic; FDA approved for the treatment of schizophrenia. 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| HY-17407R | MCE | Ziprasidone hydrochloride monohydrate (Standard),138982-67-9,盐酸齐拉西酮水合物 (标准品)_MCE(MedChemExpress) | 980元/5 mg; 1470元/10 mg; 2650元/25 mg; 3980元/50 mg; 5970元/100 mg; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 Ziprasidone hydrochloride monohydrate (Standard)MCE 国际站:Ziprasidone hydrochloride monohydrate (Standard) 品牌:MedChemExpress (MCE) 货号:HY-17407R CAS 号:138982-67-9 产品简介:Ziprasidone (hydrochloride monohydrate) (Standard)是 Ziprasidone (hydrochloride monohydrate) 的分析标准品。本产品用于研究及分析应用。Ziprasidone (CP-88059) hydrochloride monohydrate 是一种具有口服活性的 5-HT 和多巴胺 (dopamine) 受体拮抗剂。Ziprasidone hydrochloride monohydrate 对大鼠 D2 (Ki=4.8 nM)、5-HT2A (Ki=0.42 nM) 和 5-HT1A (Ki=3.4 nM) 有亲和作用。 产品应用:该化合物为分析标准品级别,是含量检测的分析标准品,常用于液相、气相和质谱的定性、定量及方法学研究实验中。 分子量:467.41 Formula:C21H24Cl2N4O2S 中文名称:盐酸齐拉西酮水合物 (标准品) 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:请按照分析证书中推荐的条件储存产品。 提供质量检测报告:产品使用指南 产品活性:Ziprasidone (hydrochloride monohydrate) (Standard)是 Ziprasidone (hydrochloride monohydrate) 的分析标准品。本产品用于研究及分析应用。Ziprasidone (CP-88059) hydrochloride monohydrate 是一种具有口服活性的 5-HT 和多巴胺 (dopamine) 受体拮抗剂。Ziprasidone hydrochloride monohydrate 对大鼠 D2 (Ki=4.8 nM)、5-HT2A (Ki=0.42 nM) 和 5-HT1A (Ki=3.4 nM) 有亲和作用。 相关产品:Pimavanserin (Standard) | Deschloroclozapine | Pimavanserin | A 83-01 (Standard) | SB-431542 (Standard) | Poly-D-lysine hydrobromide (MW 150000-300000) | SB-431542 | Poly-D-lysine hydrobromide (MW 70000-150000) | Ziprasidone hydrochloride monohydrate | Adezmapimod (Standard) | SN-38 (Standard) | Pomalidomide (Standard) 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| HY-17407 | MCE | Ziprasidone hydrochloride monohydrate,138982-67-9,盐酸齐拉西酮水合物_MCE(MedChemExpress) | 394元/10 mM * 1 mL in DMSO; 383元/5 mg; 614元/10 mg; 1030元/25 mg; 1534元/50 mg; 2388元/100 mg; | 咨询 | |||||||||||||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 Ziprasidone hydrochloride monohydrateMCE 国际站:Ziprasidone hydrochloride monohydrate 品牌:MedChemExpress (MCE) 货号:HY-17407 CAS 号:138982-67-9 生物活性:盐酸齐拉西酮(CP-88059)一水合物是一种口服有效的5-HT和多巴胺受体拮抗剂[1]。盐酸齐拉西酮一水合物对大鼠D2(Ki=4.8 nM)、5-HT2A(Ki=0.42 nM)和5-HT1A(Ki=3.4 nM)具有亲和力[1]。 体外研究(In Vitro):Ziprasidone hydrochloride monohydrate (0-500 nM, 150 seconds) blocks wild-type hERG current[2]. MCE尚未独立确认这些方法的准确性。 仅供参考。 体内研究(In Vivo):Ziprasidone hydrochloride monohydrate (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold[3]. MCE尚未独立确认这些方法的准确性。 仅供参考。 分子量:467.41 Formula:C21H24Cl2N4O2S 性状:固体 颜色:Pink to red 中文名称:盐酸齐拉西酮水合物 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式: 4°C,密封保存,避光防潮 *溶剂保存:-80°C,6个月;-20°C,1个月(密封保存,避光防潮) 文献引用:MCE 顾客使用本产品发表 4 篇科研文献 提供质量检测报告:Data Sheet、SDS、COA、HNMR、LCMS、产品使用指南 产品活性:Ziprasidone (CP-88059) hydrochloride monohydrate 是一种具有口服活性的 5-HT 和多巴胺 (dopamine) 受体拮抗剂。Ziprasidone hydrochloride monohydrate 对大鼠 D2 (Ki=4.8 nM)、5-HT2A (Ki=0.42 nM) 和 5-HT1A (Ki=3.4 nM) 有亲和作用。 相关产品:Deschloroclozapine | Pimavanserin | Pimavanserin (Standard) | Poly-D-lysine hydrobromide (MW 150000-300000) | SB-431542 | Poly-D-lysine hydrobromide (MW 84000) | Poly-D-lysine hydrobromide (MW 30000-70000) | Poly-D-lysine hydrobromide (MW 70000-150000) | Erastin | SB 202190 | SB-431542 | SB-431542 (Standard) 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 参考文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||